Protein / target
Tubulin alpha-3C chain
Protein at a glance
Biological role
Structural constituent of cytoskeleton
Primary system
Endocrine & metabolic
Strongest disease association
keratoconus 9
Druggability
Small molecule
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Tubulin is the major constituent of microtubules, a cylinder consisting of laterally associated linear protofilaments composed of alpha- and beta-tubulin heterodimers. Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms. Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin
Subcellular location
Domains and Gene Ontology detail (11)Hide
Gene Ontology
- Ccilium
- Ccytoplasm
- Cmicrotubule
- Cmicrotubule cytoskeleton
- Cnucleus
- FGTP binding
- Fhydrolase activity
- Fmetal ion binding
- Fstructural constituent of cytoskeleton
- Pmicrotubule cytoskeleton organization
- Pmitotic cell cycle
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Nuclear receptor signalling
- ·HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
Immune signalling
- ·MHC class II antigen presentation
View underlying pathways (25)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin inhibitor
Tubulin disrupting agent
Tubulin inhibitor
Tubulin inhibitor
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 49 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (24)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 10 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Trial results posted
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer (CemiHALT )
- Trial status changed
Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
- Trial results posted
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.
- Trial status changed
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma.
- Trial status changed
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- CHMP positive opinion
CHMP positive opinion: Colchicine Agepha Pharma (EMA)
- Indication expanded
Indication expansion: ENFORTUMAB VEDOTIN (BLA761137)
- Regulatory approval
Approval: Blenrep (EMA)
- Regulatory approval
Approval: Tivdak (EMA)
- New publicationPembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
- Label change
Label change: ENFORTUMAB VEDOTIN (BLA761137)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.